公开(公告)号：US06828350B1

公开(公告)日：2004-12-07

申请号：US09555421

申请日：2000-10-23

Applicant: Dorit Arad ,  Yuval Elias

Inventor： Dorit Arad ,  Yuval Elias

IPC: A61K31165

CPC classification number: A61K31/618 ,  A61K31/00 ,  A61K31/11 ,  A61K31/12 ,  A61K31/121 ,  A61K31/122 ,  A61K31/165 ,  A61K31/166 ,  A61K31/216 ,  A61K31/22 ,  A61K31/366 ,  A61K31/4152 ,  A61K31/423 ,  A61K31/44 ,  A61K31/4415 ,  A61K31/60 ,  G01N2333/085 ,  G01N2333/96466 ,  Y02A50/463 ,  Y02A50/465

Abstract: The present invention concerns novel mediators of the activity of picornavirus 3C protease and the modulation of the activity of other similar proteins. The modulators may be used in pharmaceutical compositions either for inhibition of 3C protease (for example in viral infections) or for the enhancement of the activity of proteins similar to the 3C protease such as Apopain (for induction of apoptosis).

Abstract translation: 本发明涉及小核糖​​核酸病毒3C蛋白酶的活性的新型介体以及其它类似蛋白质的活性的调节。 调节剂可以用于抑制3C蛋白酶（例如病毒感染）的药物组合物中，或用于增强类似于3C蛋白酶（如Apopain）（用于诱导凋亡）的蛋白质的活性。

公开(公告)号：US06716829B2

公开(公告)日：2004-04-06

申请号：US09915784

申请日：2001-07-26

Applicant: Ricardo Rocha ,  Marc Zack ,  Ellen McMahon ,  Eileen R. Blasi

Inventor： Ricardo Rocha ,  Marc Zack ,  Ellen McMahon ,  Eileen R. Blasi

IPC: A61K3156

CPC classification number: A61K45/06 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/437 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/57 ,  A61K31/58 ,  A61K31/585 ,  A61K2300/00

Abstract: Combinations of aldosterone blockers and Cyclooxygenase-2 inhibitors useful in the treatment of inflammation are disclosed.

Abstract translation: 公开了可用于治疗炎症的醛固酮阻滞剂和环氧合酶-2抑制剂的组合。

公开(公告)号：US20030162759A1

公开(公告)日：2003-08-28

申请号：US09916136

申请日：2001-07-26

Inventor： Ricardo Rocha ,  Marc Zack ,  Ellen McMahon ,  Eileen R. Blasi

IPC: A61K031/58

CPC classification number: A61K45/06 ,  A61K31/00 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/437 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/57 ,  A61K31/58 ,  A61K31/585 ,  A61K2300/00

Abstract: Aldosterone blockers used for the treatment and prevention of inflammation are disclosed

Abstract translation: 公开了用于治疗和预防炎症的醛固酮阻滞剂

公开(公告)号：US06552063B2

公开(公告)日：2003-04-22

申请号：US09920875

申请日：2001-08-03

Applicant: George Green

Inventor： George Green

IPC: A61K31415

CPC classification number: A61K31/4152 ,  A61K9/0056

Abstract: A formulation for delivery of phenylbutazone for the treatment of equine ailments is disbursed homogeneately in a powdered carrier agent having a flavoring agent and a coloring agent in an amount of from 5 to 49.9 percent by weight of the formulation.

公开(公告)号：US20030004143A1

公开(公告)日：2003-01-02

申请号：US10125218

申请日：2002-04-18

Inventor： Christopher P. Prior ,  Drore Eisen ,  Louis Herlands

IPC: A61K031/60 ,  A61K031/415 ,  A61K031/405 ,  A61K031/192

CPC classification number: A61K45/06 ,  A61K9/0036 ,  A61K31/00 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/19 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/381 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4152 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4365 ,  A61K31/44 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/603 ,  A61K31/616 ,  A61K2300/00

Abstract: The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the female reproductive tract.

Abstract translation: 本发明涉及非甾体抗炎药（NSAID）用于治疗和预防女性生殖道细胞异常的用途。

公开(公告)号：US06436915B1

公开(公告)日：2002-08-20

申请号：US09747563

申请日：2000-12-22

Applicant: Zaihui Zhang ,  Timothy Scott Daynard ,  Shisen Wang ,  Mikhail Chafeev

Inventor： Zaihui Zhang ,  Timothy Scott Daynard ,  Shisen Wang ,  Mikhail Chafeev

IPC: A61K31415

CPC classification number: C07D231/38 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/454 ,  A61K31/53 ,  A61K31/5377 ,  C07D231/46 ,  C07D231/52 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12

Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

公开(公告)号：US20020025978A1

公开(公告)日：2002-02-28

申请号：US09920875

申请日：2001-08-03

Inventor： George Green

IPC: A61K031/4152

CPC classification number: A61K31/4152 ,  A61K9/0056

Abstract: A formulation for delivery of phenylbutazone for the treatment of equine ailments is disbursed homogeneately in a powdered carrier agent having a flavoring agent and a coloring agent in an amount of from 5 to 49.9 percent by weight of the formulation.

Abstract translation: 用于输送用于治疗马疾病的保泰松的制剂在具有矫味剂和着色剂的粉末状载体剂中的量均匀地分配，其量为制剂重量的5至49.9重量％。

公开(公告)号：US6022563A

公开(公告)日：2000-02-08

申请号：US240809

申请日：1999-02-01

Applicant: Douglas J. Gordon

Inventor： Douglas J. Gordon

IPC: A61K9/00 ,  A61K31/4152 ,  A61K9/16

CPC classification number: A61K9/009 ,  A61K31/4152

Abstract: A powdered carrier formulation for delivery of phenylbutazone to animals contains phenylbutazone in combination with a flavoring agent and an anticaking agent.

Abstract translation: 用于将保泰松输送到动物的粉末载体制剂包含与调味剂和抗结块剂组合的保泰松。

公开(公告)号：US5962461A

公开(公告)日：1999-10-05

申请号：US11156

申请日：1998-06-18

Applicant: Aloysius O. Anaebonam ,  Emmett Clemente ,  Abdel A. Fawzy

Inventor： Aloysius O. Anaebonam ,  Emmett Clemente ,  Abdel A. Fawzy

IPC: A61K9/08 ,  A61K9/00 ,  A61K31/00 ,  A61K31/075 ,  A61K31/09 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/192 ,  A61K31/221 ,  A61K31/27 ,  A61K31/4152 ,  A61K31/43 ,  A61K31/4402 ,  A61K31/445 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/485 ,  A61K31/505 ,  A61K31/515 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/60 ,  A61K31/661 ,  A61K31/79 ,  A61K47/10 ,  A61K47/26 ,  A61K47/28 ,  A61K47/32 ,  A61K31/34

CPC classification number: A61K9/0095 ,  A61K31/00 ,  A61K31/09 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/18 ,  A61K31/192 ,  A61K31/221 ,  A61K31/27 ,  A61K31/4152 ,  A61K31/43 ,  A61K31/4402 ,  A61K31/445 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/485 ,  A61K31/505 ,  A61K31/515 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/573 ,  A61K31/60 ,  A61K31/704 ,  A61K31/79

Abstract: A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a bitter tasting drug dissolved or dispersed in an aqueous medium that is free of ethanol. That aqueous medium consists essentially of water, about 5 to about 30 weight percent polyvinylpyrrolidone, about 35 to about 55 weight percent of a C.sub.3 -C.sub.6 polyol, about 0.01 to about 0.5 weight percent ammonium glycyrrhizinate and one or more flavorants. The liquid composition is transparent and has a pleasant taste. The bitter tasting drugs claimed herein are vitamin and mineral preparations, trimethoprim, and guaifenesin.

Abstract translation: PCT No.PCT / US97 / 14018 Sec。 371日期1998年6月18日 102（e）日期1998年6月18日PCT提交1997年8月7日PCT公布。 第WO98 / 05312号公报 日期1998年2月12日考虑了包含溶解或分散在不含乙醇的水性介质中的药学有效量的苦味药物的液体药物组合物。 该水性介质基本上由水，约5至约30重量％的聚乙烯吡咯烷酮，约35至约55重量％的C 3 -C 6多元醇，约0.01至约0.5重量％的甘草酸铵和一种或多种调味剂组成。 液体组合物是透明的并且具有令人愉悦的味道。 本文所要求的苦味药是维生素和矿物质制剂，甲氧苄啶和愈创木酚。

公开(公告)号：US20240269115A1

公开(公告)日：2024-08-15

申请号：US18567807

申请日：2022-06-07

Applicant: FLONEXT S.R.L.

Inventor： Pierangelo GEPPETTI ,  Romina NASSINI ,  Francesco DE LOGU

IPC: A61K31/4152 ,  A61K9/00 ,  A61K45/06 ,  A61P27/02 ,  C07K16/22

CPC classification number: A61K31/4152 ,  A61K9/0048 ,  A61K45/06 ,  A61P27/02 ,  C07K16/22

Abstract: The present invention relates to compounds belonging to the pyrazolone class for use in the prevention and/or treatment of degenerative retinal diseases, in particular in the prevention and/or treatment of macular degeneration. The present invention also relates to a pharmaceutical composition comprising at least one compound belonging to the pyrazolone class, preferably a topical ophthalmic composition, for use in the prevention and/or treatment of degenerative retinal diseases, preferably macular degeneration.